TAFAZZIN and cardiomyopathy: Here, we report that Tafazzin loss of function in a mouse model of Barth Syndrome results in distinct alterations in cardiomyocyte gene expression, and we also identify adipocyte dysfunction as a potential contributor to Barth Syndrome cardiomyopathy, potentially through dysregulated fatty acid metabolism.